[1]Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample[J]. N Engl J Med. 2014;370:1422–1431.
[2]Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation. 2014;129 (25 Suppl 2):S1–45.
[3]Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult[J]. Can J Cardiol. 2016;32:1263–1282.
[4] WANG Wei, ZHAO Dong, LIU Jing, et al.Serum total cholesterol and 10-year cardiovascular risk in a Chinese cohort aged 35—64 years[J]. Chin J Cardiol 2006, Vol. 34, No. 2.
[5]Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366: 1267-1278.
[6]Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report[J]. J Clin Lipidol, 2015, 9: 129-169.
[7]Jellinger PS, Handelsman Y, Rosenblit PD, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE[J]. Endocr Pract. 2017; 23(Suppl2): 1-87.
[8] Joint committee issued Chinese guideline for the management of dyslipidemia in adults. 2016 Chinese guideline for the management of dyslipidemia in adults[J].Zhonghua Xin Xue Guan Bing Za Zhi. 2016 ; 44(10): 833-853.
[9]Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up[J].Circulation. 2017 Nov 14;136(20): 1878-1891.
[10]Ference BA, Yoo W, Alesh I, et al.Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis[J].J Am Coll Cardiol. 2012; 60(25): 2631-9
[11] Ohkuma T, Ninomiya T, Tomiyama H, et al.Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease: An Individual Participant Data Meta-Analysis[J].Hypertension. 2017 ;69(6): 1045-1052.
[12] Kim JH, Rhee MY, Kim YS, et al. Brachial-ankle pulse wave velocity for the prediction of the presence and severity of coronary artery disease[J].Clin Exp Hypertens. 2014;36(6):404-9.
[13]Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness[J]. Arterioscler Thromb Vasc Biol. 2005;25:932–43.
[14]Ma H, Lin H, Hu Y, et al. Relationship between non-high-density lipoprotein cholesterol and carotid arteriosclerosis in normotensive and euglycemic Chinese middle-aged and elderly adults[J]. Lipids Health Dis. 2017 ;16(1):55.
[15]Zhu WH, Zhu YM, Chen JH, et al. Brachial ankle pulse wave velocity in the patients of metabolic syndrome[J]. Zhonghua Yi Xue Za Zhi. 2013 Feb 26; 93(8): 566-8.
[16] Wu S, Huang Z, Yang X, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city[J]. Circ Cardiovasc Qual Outcomes. 2012; 5: 487–493.
[17] Wang L, Cui L, Wang Y, et al. Resting heart rate and the risk of developing impaired fasting glucose and diabetes: the Kailuan prospective study[J]. Int J Epidemiol. 2015; 44: 689–699.
[18] Jin C, Chen S, Vaidya A, et al. Longitudinal change in fasting blood glucose and myocardial infarction risk in a population without diabetes[J]. Diabetes Care. 2017; 40: 1565–1572.
[19]Huang S, Li J, Shearer GC, et al. Longitudinal study of alcohol consumption and HDL concentrations: a community-based study[J]. Am J Clin Nutr. 2017;105:905–912.
[20] Li Y, Huang Z, Jin C, et al. Longitudinal change of perceived salt intake and stroke risk in a Chinese population[J]. Stroke. 2018;49:1332–1339.
[21]Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, et al.Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease[J].Circulation. 2015 ;131(5): 451-8.
[22] Borghi C1, Veronesi M, Cosentino E, et al. Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure[J]. J Hypertens. 2007 Oct; 25(10): 2051-7.
[23] Strehlow K, Wassmann S, Böhm M, et al. Angiotensin AT1 receptor over-expression in hypercholesterolaemia[J]. Ann Med. 2000; 32: 386-389.
[24] Businaro R, Tagliani A, Buttari B, et al. Cellular and molecular players in the atherosclerotic plaque progression[J]. Ann N Y Acad Sci. 2012; 1262: 134–141.
[25] Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis[J]. Nat Rev Immunol. 2010; 10: 36–46.
[26] Tsuchikura S, Shoji T, Kimoto E, et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness[J]. J Atheroscler Thromb. 2010; 17: 658–665.